Global Anti-malarial Drugs Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Aryl amino alcohol compounds, Antifolate compounds, Artemisinin compounds, and Others

By Distribution Channel;

Hospital Pharmacy, E-Commerce, Retail Pharmacy, and Others

By Malaria Type;

Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malaria, and Plasmodium Ovule

By End User;

Hospitals, Specialty Clinics, Homecare, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn147974443 Published Date: June, 2025 Updated Date: July, 2025

Anti-malarial Drugs Market Overview

Anti-malarial Drugs Market (USD Million)

Anti-malarial Drugs Market was valued at USD 9,059.93 million in the year 2024. The size of this market is expected to increase to USD 11,456.78 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 3.4%.


Global Anti-malarial Drugs Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 3.4 %


Study Period2025 - 2031
Base Year2024
CAGR (%)3.4 %
Market Size (2024)USD 9,059.93 Million
Market Size (2031)USD 11,456.78 Million
Market ConcentrationHigh
Report Pages332
9,059.93
2024
11,456.78
2031

Major Players

  • Cipla
  • Novartis AG
  • Strides Pharma Science Limited
  • Glenmark Pharmaceuticals
  • GlaxoSmithKline PLC

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Anti-malarial Drugs Market

Fragmented - Highly competitive market without dominant players


The Anti-malarial Drugs Market is expanding as global efforts intensify to combat widespread malaria infections. Over 40% of at-risk populations continue to face exposure, increasing the demand for more effective treatment options. The emergence of drug-resistant malaria strains is further accelerating innovation in combination therapies and advanced pharmaceutical solutions.

Institutional Backing Fueling Market Momentum
Support from government bodies and health organizations is strengthening the market, with more than 50% of malaria eradication programs relying on public-private alliances. These initiatives are boosting funding levels, expanding access to medications, and embedding anti-malarial treatment in public health strategies.

Preventive Drug Adoption on the Rise
Efforts to raise public awareness have led to a notable 20% reduction in advanced malaria cases. Educational programs and access to preventive medications have played a critical role in early intervention, especially among high-risk groups and international travelers.

Overcoming Market Barriers and Unlocking Growth
The market still faces issues such as regulatory hurdles, inconsistent drug supply, and limited access in underserved areas. Despite these obstacles, strategic collaborations and increased investment in clinical trials (over 35%) indicate growing potential for therapeutic breakthroughs and market growth.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Distribution Channel
    3. Market Snapshot, By Malaria Type
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Anti-malarial Drugs Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Drug Resistance

        2. Public Health Initiatives

        3. Research & Development

      2. Restraints
        1. Limited Access

        2. Drug Affordability

        3. Pandemic Impact

      3. Opportunities
        1. Innovative Therapies

        2. Public-Private Partnerships

        3. Expanded Distribution Networks

    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Anti-malarial Drugs Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Aryl amino alcohol compounds

      2. Antifolate compounds

      3. Artemisinin compounds

      4. Others

    2. Anti-malarial Drugs Market, By Distribution Channel, 2021 - 2031 (USD Million)

      1. Hospital Pharmacy

      2. E-Commerce

      3. Retail Pharmacy

      4. Others

    3. Anti-malarial Drugs Market, By Maleria Type, 2021 - 2031 (USD Million)
      1. Plasmodium Falciparum

      2. Plasmodium Vivax

      3. Plasmodium Malarie

      4. Plasmodium Ovale

    4. Anti-malarial Drugs Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Specialty Clinics
      3. Homecare
      4. Others
    5. Anti-malarial Drugs Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Cipla
      2. Novartis AG
      3. Strides Pharma Science Limited
      4. Glenmark Pharmaceuticals
      5. GlaxoSmithKline PLC
  7. Analyst Views
  8. Future Outlook of the Market